31 results about "Endothelial cell-cell adhesion" patented technology

Endothelial cell attachment to an intravascular stent is promoted by coating the stent with an endothelial cell specific adhesion peptide. Coating is preferably carried out by activating the intravascular stent using plasma glow discharge, applying on the stent a layer or plurality of layers of a polymer such as poly(2-hydroxyethylmethacrylate), applying a tresylation solution containing pyridine and tresyl chloride, and applying a five amino acid peptide having the sequence glycine-arginine-glutamic acid-aspartic acid-valine.

This invention provides compositions and methods for producing a medical device coated with a matrix and an antibody which reacts with an endothelial cell antigen. The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin, amorphous carbon. In a third embodiment, the matrix may be composed of fullerenes. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote adherence of endothelial cells on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following adherence to the medical device, the endothelial cells differentiate and proliferate on the medical device. The antibodies may be different types of monoclonal antibodies. Methods of preparing such composition and methods of treating a mammal with atherosclerosis or other types of vessel obstruction are disclosed. By facilitating adherence of endothelial cells to the surface of the medical device, the methods and compositions of this invention will decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

A medical device having a coating of cell adhesion polypeptides to enhance endothelial cell adhesion onto the medical device. The cell adhesion polypeptides may be any of the proteins of the extracellular matrix which are known to play a role in cell adhesion or derivative peptides such as RGD or YIGSR. The polypeptides may be incorporated into the backbone of a polymer such as polyurethane, or grafted onto a polymer such polybisphosphonate. The polypeptides may also be carried on antibodies or displayed on bacteriophages. The polypeptides may also be modified to have adhesive amino acid sequences. In certain embodiments, the medical device further comprises a temporary barrier that protects the polypeptides from biofouling. The temporary barrier may be formed of a biodegradable polymer and be constructed as a coating over the polypeptides or as a plurality of micelles encapsulating the polypeptides. In certain embodiments, the polypeptides may be coated onto the medical device in such a manner as to form a monolayer of the polypeptides.

The present invention relates to a method and pharmaceutical composition for preventing or treating inflammatory diseases. More particularly, the present invention relates to a method for inhibiting lymphocyte adhesion to an endothelial cell, or a method for treating an inflammatory disease, which comprises administering to a subject in need thereof an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide. A pharmaceutical composition comprising the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, and the use of the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide are also disclosed. Further, a method for screening a medicament for inhibiting lymphocyte adhesion to a FEX-2 polypeptide or a medicament for treating an inflammatory disease, which comprises a step of selecting an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, is disclosed.

The invention relates to the field of biomedical materials and provides coating to promote vascular intimal repairing. An amino-containing polypeptide and a copper-based MOF (metal-organic framework)are grafted to the surface of the coating; the amino-containing polypeptide is capable of specifically promoting adhesion of endothelial cells. A material to promote vascular intimal repairing comprises a substrate material; the coating to promote vascular intimal repairing is attached to the surface of the substrate material. A preparation method of the material to promote vascular intimal repairing comprises coating the surface of the substrate material with the copper-based MOF and the coating which the amino-containing polypeptide is grafted to; the amino-containing polypeptide can specifically promote adhesion of the endothelial cells; a medical product is made with the above material to promote vascular intimal repairing. All the coating, the material and the medical product providedherein can specifically promote adhesion and growth of endothelial cells, and reduce damage to the endothelial cells in a peroxidation micro environment.

The invention discloses application of sodium butyrate in preparing medicine used for treating and restraining diseases or symptoms relevant to blood vessel permeability enhancement or postponing outbreak of the diseases or symptoms or abating the caused diseases or symptoms. The sodium butyrate can increase the expression of vascular endothelial cell adherent junction gap-associated protein p120 on the oxygen deficit condition, endothelial cell adherent junction stability is kept, and blood vessel endothelium permeability is restrained from being increased on the oxygen deficit condition; the sodium butyrate is soluble in an aqueous solution and stable in property, and not matter dry powder or the aqueous solution can be preserved at normal temperature. The sodium butyrate can be completely and directly absorbed by the intestinal tract, secondary degradation is avoided, and the price is low.

The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.

The invention belongs to the technical field of medicines, and discloses application of IELLQAR as medicine for preventing and treating atherosclerosis diseases. The IELLQAR can inhibit the binding ofmononuclear cells and P, E and L selection glycoprotein so as to inhibit the adhesion of mononuclear cells and endothelial cells, and also has a function of inhibiting inflammation. An ApoE gene mouse is induced by high fat diet, then obvious atherosclerosis plaques can be seen in the aorta, IELLQAR intervention can retard ApoE gene knockout mouse atherosclerosis lesions, and local mononuclear macrophage infiltration of atherosclerosis plaques can be reduced. Animal experiments and in vitro cell research levels indicate that the IELLQAR can inhibit mononuclear cell adhesion and inflammatory factor expression, atherosclerosis progress can be inhibited through an anti-inflammatory mechanism, atherosclerosis-related diseases can be prevented and treated, and therefore, the IELLQAR has an important clinical application prospect.

The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.

The invention discloses a rH-PLGA/PEI microspheres and dopamine modified small-caliber intravascular stent material and a preparation method thereof. The method comprises the following steps: preparing a PCL nanofiber scaffold as a substrate by using an electrostatic spinning technology, depositing a layer of dopamine on the surface of the PCL nanofiber scaffold, and loading PLGA/PEI microspheres wrapped with hirudin on PCL nanofibers by using the adhesion of the dopamine to obtain the small-caliber intravascular stent material. According to the method, hirudin, PLGA/PEI microspheres and dopamine are combined, the obtained stent can prevent thrombus and promote rapid endothelialization and revascularization for a long time, the process is simple and feasible, and repeatability is good. The small-caliber intravascular stent has good biocompatibility, and the vascular tissue repair speed and quality are accelerated by utilizing the promotion effect and anticoagulant effect of hirudin on endothelial cell adhesion and proliferation.

The invention discloses an in-vivo implant capable of promoting adhesion and differentiation of endothelial cells, an internal area of the implant is made of a degradable material and plays a role in throughout and always supporting the implant, a middle area is formed by compounding the degradable material and a first drug, and an external area is formed by compounding an organic polymer material and a second drug and plays a role in throughout and always supporting the implant. The first medicine is an anti-restenosis medicine for inhibiting smooth muscle cell proliferation, the second medicine is a specific endothelial progenitor cell antibody capturing medicine, and the proportion of the second medicine in an external area is gradually changed, so that the adhesion and differentiation capabilities of endothelial cells around a tissue injury part are improved, and the tissue injury effect is improved. And meanwhile, after the expected repairing purpose is achieved, the slow release of the first medicine is utilized to inhibit the cell proliferation so as to prevent the occurrence of restenosis. The variable stacking form can adapt to the structural characteristics of the human body, the requirements of different patients and different implantation positions are met, the operation is safer and more reliable, and the postoperative curative effect is better.

The invention relates to difunctional polyurethane and a preparation method and application thereof, and belongs to the technical field of biologic medical materials. The technical problem that an existing blood vessel material cannot eliminate oxidative stress of a blood vessel implant part is solved. The difunctional polyurethane contains a ligustrazine-nitrone group, and the structural formula of the ligustrazine-nitrone group is shown in the formula I. According to the difunctional polyurethane, by introducing a polyurethane molecular chain (tail end) into the ligustrazine-nitrone group with the dual functions of anti-oxidant and endothelial cell sticking promotion, the dual functions of polyurethane anti-oxidation and endothelial cell sticking promotion are given, adhesion and multiplication of endothelial cells can be effectively promoted, and the normal functions of the endothelial cells are promoted under the oxidation stress environment.